candesartan has been researched along with osteoprotegerin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bandow, K; Iwabuchi, S; Kakimoto, K; Kuroe, K; Matsuguchi, T; Nishikawa, Y; Ohnishi, T; Soejima, K | 1 |
| Gavish, D; Hass, A; Oz, H; Shargorodsky, M | 1 |
1 trial(s) available for candesartan and osteoprotegerin
| Article | Year |
|---|---|
Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Bone and Bones; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Osteoprotegerin; Renin-Angiotensin System; Tetrazoles | 2015 |
1 other study(ies) available for candesartan and osteoprotegerin
| Article | Year |
|---|---|
Low-intensity pulsed ultrasound (LIPUS) induces RANKL, MCP-1, and MIP-1beta expression in osteoblasts through the angiotensin II type 1 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cell Differentiation; Chemokine CCL2; Chemokine CCL4; Chemokine CCL5; Chemokines, CC; Extracellular Signal-Regulated MAP Kinases; Mechanotransduction, Cellular; Mice; Osteoblasts; Osteoprotegerin; Phosphorylation; RANK Ligand; Receptor, Angiotensin, Type 1; RNA, Messenger; Stress, Mechanical; Tetrazoles; Time Factors; Ultrasonic Therapy; Up-Regulation | 2007 |